Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EY9F | ISIN: US98987D2018 | Ticker-Symbol:
NASDAQ
19.04.24
18:26 Uhr
0,600 US-Dollar
-0,026
-4,15 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ZYVERSA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ZYVERSA THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ZYVERSA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiZyVersa Therapeutics, Inc. - 8-K, Current Report1
04.04.ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes79Atherosclerosis (AS) and its sequelae are the most common cause of death in diabetic patients and one of the reasons why diabetes has entered the top 10 causes of death worldwide.The published data...
► Artikel lesen
25.03.ZyVersa Therapeutics GAAP EPS of -$0.293
25.03.ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update124Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney disease H1-2024.Inflammasome ASC Inhibitor IC 100 preclinical program...
► Artikel lesen
25.03.ZyVersa Therapeutics, Inc. - 10-K, Annual Report2
18.03.ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease94Phase 2a trial is on track to begin in the first half of 2024.Cholesterol Efflux MediatorTM VAR 200 is in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system...
► Artikel lesen
14.03.ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled "Inflammation Illuminated,"at Benzinga's Virtual Healthcare Summit 2024 on March 20, 20242
08.03.ZyVersa Therapeutics, Inc. - 8-K, Current Report1
01.03.ZyVersa Therapeutics, Inc. - 8-K, Current Report4
29.02.ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity151ZyVersa is developing Inflammasome ASC Inhibitor IC 100, which is designed to inhibit formation of multiple types of inflammasomes, including NLRP3, and their associated ASC specks to attenuate initiation...
► Artikel lesen
28.02.ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications131Obesity, which affects over 1.9 billion people worldwide, is a state of low-grade chronic inflammation that causes an array of different metabolic disorders, including insulin resistance, type 2 Diabetes...
► Artikel lesen
26.02.Microcap ZyVersa up 71% on study supporting new way to fight obesity7
26.02.What In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?7
26.02.Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?7
22.02.ZyVersa reports progress on neurological inflammation drug3
22.02.ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option1
14.02.ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases137Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and cognitive disability, and 1.2 million new cases are diagnosed annually. The review article...
► Artikel lesen
07.02.ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones-
31.01.ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes236Insulin resistance (IR), a common feature of childhood obesity which affects 15 million children and adolescents, is the main driver of obesity-related metabolic complications such as Type 2 diabetes...
► Artikel lesen
24.01.ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease171Research demonstrated that activation of the inflammasome/ASC speck pathway has a vital role in synaptic degeneration in Alzheimer's Disease (AD).ZyVersa is developing IC 100, a monoclonal antibody...
► Artikel lesen
Seite:  Weiter >>
62 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1